ARS Pharmaceuticals, Inc. — Director's Dealing 2020

Dec 4, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2020-12-03

Reporting Person: HERSHBERG ROBERT (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock option (right to buy)	$2.31	2027-05-16	Common Stock (38098)		Direct
Stock option (right to buy)	$1.27	2030-05-22	Common Stock (6863)		Direct
Stock option (right to buy)	$1.27	2030-05-22	Common Stock (13704)		Direct
Stock option (right to buy)	$1.27	2030-05-22	Common Stock (14209)		Direct

Footnotes

F1: The shares shall vest in 48 equal monthly installments beginning on March 14, 2017.

F2: The shares shall vest in 36 equal monthly installments beginning on April 4, 2020.

F3: The shares shall vest in 36 equal monthly installments beginning on August 1, 2020.

F4: The shares shall vest in 36 equal monthly installments beginning on October 18, 2020.